Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2024
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III TrialMarianne Sinn, Marcus Bahra, Torsten Liersch, et al.
Annals of Hematology|September 19, 2003
Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)Hermann Einsele, Hartmut Bertz, Jörg Beyer, et al.
Gastroenterology|May 24, 2016
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer CellsEngin Gürlevik, Bettina Fleischmann-Mundt, Jennifer Brooks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2025
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 TrialRainer Fietkau, Michael Ghadimi, Robert Grützmann, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Nature Communications|January 11, 2022
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expressionPhyllis F Cheung, JiaJin Yang, Rui Fang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2023
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trialRolf D Issels, Stefan Boeck, Uwe Pelzer, et al.
Pageof 5